Harrow Health (NASDAQ:HROW) announced its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03), Fidelity Earnings reports. Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The firm had revenue of $13.52 million for the quarter, compared to analyst estimates of $12.55 million.
Shares of NASDAQ HROW traded down $1.64 during midday trading on Thursday, reaching $4.76. 78,090 shares of the company traded hands, compared to its average volume of 253,168. Harrow Health has a 52 week low of $2.22 and a 52 week high of $8.99. The stock’s 50-day moving average is $7.66. The company has a current ratio of 3.43, a quick ratio of 3.22 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $157.36 million, a P/E ratio of 7.94 and a beta of 0.06.
In related news, Director Robert J. Kammer sold 6,500 shares of Harrow Health stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $7.91, for a total transaction of $51,415.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $5.78, for a total transaction of $57,800.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,000 shares of company stock worth $154,000. Company insiders own 12.43% of the company’s stock.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
See Also: Google Finance Portfolio Workaround
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.